Kala Bio, INC DEF 14A proxy statements

Kala Bio, Inc. filed a supplement to its 2025 Annual Meeting proxy statement, updating the biography of Class II Director Nominee David Lazar to reflect his recent and current executive and board roles across multiple public companies.

Kala Bio, Inc. filed a supplement to its 2025 Proxy Statement, detailing new related party share issuances and an updated count of outstanding common stock.

KALA BIO, Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, executive compensation, auditor ratification, preferred stock conversion, increased authorized shares, and a reverse stock split.

KALA BIO is reminding stockholders to vote on proposals for the upcoming annual meeting on June 11, 2024.

KALA BIO, INC. is holding its annual meeting on June 11, 2024, seeking stockholder votes on director elections, executive compensation, auditor ratification, stock issuance, and amendments to preferred stock designations.

KALA BIO is asking stockholders to vote on the election of directors, executive compensation, auditor ratification, and amendments to preferred stock designations at its annual meeting on June 11, 2024.